Epigenomics Request Triggers CMS Plan To Cover Colorectal Cancer Blood-Based Biomarker Tests

The US Centers for Medicare and Medicaid Services is considering a national coverage determination for a blood-based biomarker screening test for colorectal cancer after receiving a request for a national coverage determination from Epigenomics for its Epi proColon assay.

MT2003_Array of blood_motorolka_135200900_1200.jpg

The US Centers for Medicare and Medicaid Services on 28 February opened up a national coverage analysis tracking sheet on blood-based biomarker screening tests for colorectal cancer. The CMS tracking sheet was triggered by a request from Epigenomics to consider coverage of its Epi proColon assay.

In an April 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight